Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon

Lyon, April 20th, 2015 - Adocia (Euronext Paris: FR0011184241 - ADOC) will hold its annual shareholders’ meeting (“AGM”) on May 27, 2015, at 10:30 am at Château de Montchat, Place du Château in Lyon (69003).

The notice of this shareholders’ meeting published today, in the French official legal bulletin (“BALO”) includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting. This notice is also available on the company’s website: http://www.adocia.fr/WP/investors-welcome/shareholders-meeting.

All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the company’s website from May 5, 2015.

Precision regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend the annual shareholders’ meeting.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” (certificate of shareholding) must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The “attestation de participation” (certificate of shareholding) may replace the admission card for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM at the latest four business days prior to the AGM (by recorded letter, addressed to the registered office, or by e-mail to contactinvestisseur@adocia.com).

Shareholders may obtain the legal documentation in preparation of the AGM as described in the article R.225-83 of the French Commercial Code by sending a request:

- By regular mail to: Adocia - Service Relations Investisseurs – 115 avenue Lacassagne, 69003 Lyon, or
- By e-mail to: contactinvestisseur@adocia.com.
About Adocia

To be a global leader in the innovative delivery of insulins and therapeutic proteins

Adocia is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of its new formulation of insulin lispro, BioChaperone Lispro, previously tested successfully in two phase Ib/IIa studies.

Adocia will continue to develop its fast-acting human insulin formulation internally. Two clinical studies are planned over 2015, a post-meal glucose control study with HinsBet U100 and a PK/PD study with HinsBet U500. Adocia is also actively continuing the development of its BioChaperone Combo, a unique combination of insulin Glargine, the gold-standard of basal insulin and insulin Lispro, a fast-acting insulin analog. A dose-response clinical study (Phase IIa) is scheduled for the second quarter of 2015.

In addition, Adocia launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB) in August 2014.

Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.

Fighting cancer with targeted treatments

DriveIn® is a nanotechnology which is intended to significantly improve delivery of active compounds into cancer cells. This new proprietary platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

« Innovative medicine for everyone, everywhere »

Adocia’s therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech index.

American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit: www.adocia.com

For more information please contact:

Adocia
Gérard Soula
Chairman and CEO of Adocia
contactinvestisseurs@adocia.com
Tel.: +33 4 72 610 610

Adocia Press Relations
ALIZE RP
Caroline Carmagnol
caroline@alizerp.com
adocia@alizerp.com
Tel.: + 33 1 44 54 36 61